Apremilast ESTEEM Program Meets Prima...

Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint...

There are 2 comments on the PR-inside.com story from Jan 7, 2013, titled Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint.... In it, PR-inside.com reports that:

Celgene International Sarl, a subsidiary of Celgene Corporation , today announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM 1 & 2 phase III studies.

Join the discussion below, or Read more at PR-inside.com.

Since: Sep 12

Location hidden

#1 Jan 7, 2013
As study found that 10 to 30 percent of psoriasis patient develop psoriatic arthritis, but there may some precautions to avoid these as it causes joint pain, joint stiffness and swelling.

Austin, TX

#2 Jan 15, 2013
To learn more about Apremilast, check out http://www.rxwiki.com/apremilast

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Healthcare Industry Discussions

Title Updated Last By Comments
News Explosion In School Lab Injures 2 Students (Dec '08) Jul 14 downwithhyde 29
News Teva Announces Launch of Generic Zoloft (Nov '06) Jul 13 Liz 1,482
News State Kicks Kool Smiles in the Teeth (Aug '07) Jul 12 Tolerman 421
News Pfizer agrees to note addiction risks in opioid... Jul 7 BHM5267 2
News Texas Attorney General sues network marketing c... (Jul '07) Jun '16 Cynthia Gosney 5
News Woman is shot on Park Street in Dorchester Jun '16 bozo 1
News Chelsea Clinton gives birth to second child, so... Jun '16 Hostis Publicus 11
More from around the web